Company Analysis
Sign in

AbCellera Biologics Inc. (ABCL)

Nasdaq: ABCL · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.8
◀ Past 6.7● Present 5.7▶ Future 5.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AbCellera Biologics Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 4 in 2024 and none in 2023
Applications published
32
2 of them in 2025
Names they are printed under
4
a subsidiary, its own name
By yearGrantedApplications published
'13'14'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology5
Pharmaceuticals2
Other special machines1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
TRIANNI, INC. a subsidiary
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in CA)
0 granted
23 published
TRIANNI, INC. a subsidiary
US, as the owner printed on each patent
10 granted
2 published
AbCellera Biologics Inc. its own name
CA, as the owner printed on each patent
1 granted
6 published
AbCellera Biologics Inc. its own name
named as the applicant on its applications, in CA
0 granted
1 published
Names not counted (2)
Lineage Biosciences Inc.
Most of its patents print CA; this name counts in US. 0 granted and 7 published under it are not counted.
Lineage Biosciences Inc.
Most of its patents print CA; this name counts in US. 3 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 24, 202412,172,038Anti-coronavirus antibodies and methods of usePharmaceuticalsAbCellera Biologics Inc.
Jul 30, 202412,049,516Transgenic mammals and methods of use thereofBiotechnologyTRIANNI, INC.
Apr 2, 202411,946,063Long germline DH genes and long HCDR3 antibodiesBiotechnologyTRIANNI, INC.
Feb 6, 202411,889,821Enhanced immunoglobulin diversityBiotechnologyTRIANNI, INC.
Aug 16, 202211,414,478Single chain VH and heavy chain antibodiesOther special machinesTRIANNI, INC.
Jul 12, 202211,384,146BTLA-binding antibodies for modulating immune response and treating diseasePharmaceuticalsTRIANNI, INC.
Jul 6, 202111,053,288Enhanced production of immunoglobulinsBiotechnologyTRIANNI, INC.
Jan 5, 202110,881,084Transgenic animals and methods of useBiotechnologyTRIANNI, INC.
Oct 27, 202010,813,346Enhanced immunoglobulin diversityBiotechnologyTRIANNI, INC.
Oct 6, 202010,793,829Transgenic mammals and methods of use thereofBiotechnologyTRIANNI, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0364074Antibody Competition Model Using Hidden Variable AffinitiesComputer technologyAbCellera Biologics Inc.
Oct 16, 20252025/0320520TRANGENIC RODENTS FOR CELL LINE IDENTIFICATION AND ENRICHMENTBiotechnologyAbCellera Biologics Inc.
Dec 26, 20242024/0423175TRANSGENIC MAMMALS AND METHODS OF USE THEREOFBiotechnologyTRIANNI, INC.
Jul 4, 20242024/0215556TRANSGENIC RODENTS EXPRESSING CHIMERIC EQUINE-RODENT ANTIBODIES AND METHODS OF USE THEREOFBiotechnologyTRIANNI, INC.
May 30, 20242024/0175049LONG GERMLINE DH GENES AND LONG HCDR3 ANTIBODIESBiotechnologyTRIANNI, INC.
May 16, 20242024/0156071ENHANCED IMMUNOGLOBULIN DIVERSITYBiotechnologyTRIANNI, INC.
May 9, 20242024/0150438Anti-Coronavirus Antibodies and Methods of UsePharmaceuticalsAbCellera Biologics Inc. · patent 12,172,038 granted from it
Jan 25, 20242024/0023526HEAVY CHAIN-ONLY ANTIBODIESBiotechnologyTRIANNI, INC.
Oct 26, 20232023/0340123BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASEPharmaceuticalsTRIANNI, INC.
Sep 21, 20232023/0295310CD3 T-Cell Engagers and Methods of UseBiotechnologyAbCellera Biologics Inc.
What it applied for, 2024 to 2025: Biotechnology 6 · Pharmaceuticals 1 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ABCL · research, not advice